| Date Filed | Type | Description |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 12/28/2022 |
RW
| Form RW - Registration Withdrawal Request: |
| 11/01/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/12/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/05/2022 |
8-K
| Quarterly results |
| 02/22/2022 |
4
| KING STEVEN W (President and CEO) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Acquired options to buy
@ $20000, valued at
$0 |
|
| 02/22/2022 |
4
| FELCYN GLORIA (Director) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Acquired options to buy
@ $25000, valued at
$0 |
|
| 02/22/2022 |
4
| GARNICK ROBERT L (Director) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Acquired options to buy
@ $50000, valued at
$0 |
|
| 02/22/2022 |
4
| BAFFI ROBERT (Director) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Acquired options to buy
@ $50000, valued at
$0 |
|
| 02/22/2022 |
4
| Steinmetz Nicole Franziska (10% Owner) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Acquired options to buy
@ $10000, valued at
$0 |
|
| 02/22/2022 |
8-K
| Quarterly results |
| 02/03/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 01/25/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 11/02/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 08/03/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 07/16/2021 |
3
| BAFFI ROBERT (Director) has filed a Form 3 on Mosaic ImmunoEngineering Inc. |
| 06/25/2021 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 06/15/2021 |
8-K
| Quarterly results |
| 06/15/2021 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
| 05/10/2021 |
4
| GARNICK ROBERT L (Director) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Acquired options to buy
@ $100000, valued at
$0 |
|
| 05/10/2021 |
4
| FELCYN GLORIA (Director) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Acquired options to buy
@ $25000, valued at
$0 |
|
| 05/10/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 04/30/2021 |
4
| Steinmetz Nicole Franziska (10% Owner) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Granted 5,357 restricted stock units
@ $2.8, valued at
$15k
|
|
| 03/09/2021 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/02/2021 |
10-KT
| Form 10-KT - Transition reports [Rule 13a-10 or 15d-10]: |
| 01/29/2021 |
4
| Steinmetz Nicole Franziska (Acting CSO) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Converted 1,641,252 shares
@ $0
Converted 570,870 shares
@ $0
Converted 161,000 options to buy
@ $0
Converted 56,000 options to buy
@ $0 |
|
| 01/29/2021 |
4
| LYTLE PAUL J (EVP, CFO) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Converted 1,641,252 shares
@ $0
Converted 161,000 options to buy
@ $0 |
|
| 01/29/2021 |
4
| KING STEVEN W (President and CEO) has filed a Form 4 on Mosaic ImmunoEngineering Inc.|
Txns:
| Converted 1,641,252 shares
@ $0
Converted 161,000 options to buy
@ $0 |
|
|